Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemarituzumab monotherapy in FGFR2b-overexpressing solid tumors
NL-OMON55987Phase 2Terminated
- Sponsor
- Amgen
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bemarituzumab in Nonhematologic neoplasms, head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC) and 7 more, sponsored by Amgen. Primary endpoints: Dose-limiting toxicities, Treatment-emergent adverse events and 1 more. Started Apr 2023; status: terminated.
02
Drugs
bemarituzumab
03
Conditions
Nonhematologic neoplasmshead and neck squamous cell carcinoma (HNSCC)triple-negative breast cancer (TNBC)intrahepatic cholangiocarcinoma (ICC)Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on NL-OMON55987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55987.